These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 21402691

  • 1. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
    Lindenbach D, Ostock CY, Eskow Jaunarajs KL, Dupre KB, Barnum CJ, Bhide N, Bishop C.
    J Pharmacol Exp Ther; 2011 Jun; 337(3):755-65. PubMed ID: 21402691
    [Abstract] [Full Text] [Related]

  • 2. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
    Barnum CJ, Eskow KL, Dupre K, Blandino P, Deak T, Bishop C.
    Neuroscience; 2008 Sep 22; 156(1):30-41. PubMed ID: 18687386
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
    Barnum CJ, Bhide N, Lindenbach D, Surrena MA, Goldenberg AA, Tignor S, Klioueva A, Walters H, Bishop C.
    Pharmacol Biochem Behav; 2012 Jan 22; 100(3):607-15. PubMed ID: 21978941
    [Abstract] [Full Text] [Related]

  • 5. The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
    Buck K, Ferger B.
    Synapse; 2010 Feb 22; 64(2):117-26. PubMed ID: 19771592
    [Abstract] [Full Text] [Related]

  • 6. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C, Crossman AR, Ravenscroft P.
    Exp Neurol; 2013 Sep 22; 247():476-84. PubMed ID: 23360800
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
    Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Bishop C.
    Behav Brain Res; 2014 Aug 15; 270():75-85. PubMed ID: 24837745
    [Abstract] [Full Text] [Related]

  • 9. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E, Lisci C, Stancampiano R, Fidalgo C, Collu M, Devoto P, Carta M.
    Neurobiol Dis; 2013 Dec 15; 60():108-14. PubMed ID: 24004632
    [Abstract] [Full Text] [Related]

  • 10. Striatal Nurr1 Facilitates the Dyskinetic State and Exacerbates Levodopa-Induced Dyskinesia in a Rat Model of Parkinson's Disease.
    Sellnow RC, Steece-Collier K, Altwal F, Sandoval IM, Kordower JH, Collier TJ, Sortwell CE, West AR, Manfredsson FP.
    J Neurosci; 2020 Apr 29; 40(18):3675-3691. PubMed ID: 32238479
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS, Zhao TT, Park KH, Park HJ, Hwang BY, Lee CK, Lee MK.
    BMC Neurosci; 2015 Apr 21; 16():23. PubMed ID: 25896846
    [Abstract] [Full Text] [Related]

  • 15. Identification of metabolite biomarkers for L-DOPA-induced dyskinesia in a rat model of Parkinson's disease by metabolomic technology.
    Wang Y, Zhang GJ, Sun YN, Yao L, Wang HS, Du CX, Zhang L, Liu J.
    Behav Brain Res; 2018 Jul 16; 347():175-183. PubMed ID: 29551735
    [Abstract] [Full Text] [Related]

  • 16. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug 16; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
    Conti MM, Ostock CY, Lindenbach D, Goldenberg AA, Kampton E, Dell'isola R, Katzman AC, Bishop C.
    Neuropharmacology; 2014 Feb 16; 77():1-8. PubMed ID: 24067924
    [Abstract] [Full Text] [Related]

  • 19. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H, Takahata K, Okano M, Ishikawa T, Satoyoshi H, Nishimura T, Hoshino N, Muraoka S.
    Behav Brain Res; 2018 Jul 16; 347():350-359. PubMed ID: 29526790
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.